Polar body array CGH for prediction of the status of the corresponding oocyte. Part I: clinical results by Geraedts, Joep et al.
ORIGINAL ARTICLE Reproductive genetics
Polar body array CGH for prediction of
the status of the corresponding oocyte.
Part I: clinical results
JoepGeraedts1,*,MarkusMontag2,M.CristinaMagli3,SjoerdRepping4,
Alan Handyside5, Catherine Staessen6, Joyce Harper7,8,
Andreas Schmutzler9, John Collins10, Veerle Goossens11,
Hans van der Ven2, Katerina Vesela12, and Luca Gianaroli3
1Department of Genetics and Cell Biology, Research Institute GROW, Faculty of Health, Medicine and Life Sciences, Maastricht University,
PO Box 5800, Maastricht, AZ 6202, The Netherlands
2Department of Gynecological Endocrinology & Reproductive Medicine, University of
Bonn, Bonn, Germany
3Department of Reproductive Medicine, SISMER, Via Mazzini 12, Bologna 40138, Italy
4Center for Reproductive
Medicine, Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5London Bridge Fertility, Gynaecology and Genetics Centre, London and Faculty of Biological Sciences, University of Leeds, Leeds, UK
6Center for Medical Genetics, University Hospital, Brussels, Belgium
7UCL Centre for PG&D, Institute for Women’s Health, University
College London, London, UK
8Centre for Reproductive and Genetic Health, UCLH, London, UK
9Center for Reproductive Medicine,
University Women’s Hospital, Christian-Albrechts-University Kiel, Kiel, Germany
10Department of Obstetrics & Gynecology, McMaster
University, Hamilton, Canada
11ESHRE Central Ofﬁce, Grimbergen, Belgium
12Sanatorium Repromeda, Brno, Czech Republic
*Correspondence address. Tel: +31-43-3875840; Fax: +31-43-3877877; E-mail: joep.geraedts@mumc.nl
Submitted on July 29, 2011; resubmitted on July 29, 2011; accepted on August 9, 2011
background: Several randomized controlled trials have not shown a beneﬁt from preimplantation genetic screening (PGS) biopsy of
cleavage-stage embryos and assessment of up to 10 chromosomes for aneuploidy. Therefore, a proof-of-principle study was planned to
determine the reliability of alternative form of PGS, i.e. PGS by polar body (PB) biopsy, with whole genome ampliﬁcation and
microarray-based comparative genomic hybridization (array CGH) analysis.
methods: In two centres, all mature metaphase II oocytes from patients who consented to the study were fertilized by ICSI. The ﬁrst and
second PBs (PB1and PB2) were biopsied and analysed separately for chromosome copy number by array CGH. If either or both of the PBs
were found to be aneuploid, the corresponding zygote was then also processed by array CGH for concordance analysis.
results: Both PBs were biopsied from a total of 226 zygotes from 42 cycles (average 5.5 per cycle; range 1–15) in 41 couples with an
average maternal age of 40.0 years. Of these, the ploidy status of the zygote could be predicted in 195 (86%): 55 were euploid (28%) and 140
were aneuploid (72%). With only one exception, there was at least one predicted aneuploid zygote in each cycle and in 19 out of 42 cycles
(45%), all zygotes were predicted to be aneuploid. Fresh embryos were transferred in the remaining 23 cycles (55%), and one frozen transfer
was done. Eight patients had a clinical pregnancy of which seven were evolutive (ongoing pregnancy rates: 17% per cycle and 30% per trans-
fer). The ploidy status of 156 zygotes was successfully analysed by array CGH: 38 (24%) were euploid and 118 (76%) were aneuploid. In 138
cases complete information was available on both PBs and the corresponding zygotes. In 130 (94%), the ploidy status of the zygote was
concordant with the ploidy status of the PBs and in 8 (6%), the results were discordant.
conclusions: This proof-of-principle study indicates that the ploidy of the zygote can be predicted with acceptable accuracy by array
CGH analysis of both PBs.
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Introduction
Until recently, ﬂuorescent in situ hybridization (FISH) of blastomeres,
biopsied at the cleavage stage, was thought to be the best method
for screening human preimplantation embryos for numerical
chromosome abnormalities, a major presumed factor causing low
pregnancy rates in medically assisted reproduction. Initially, many low-
level evidence studies suggested a favourable outcome of preimplanta-
tion genetic screening (PGS) of aneuploidy with FISH on implantation
and pregnancy rates (Gianaroli et al., 1999; Munne et al., 2003, 2005,
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trials (RCT) has not conﬁrmed these initially promising ﬁndings.
There are now at least 10 RCTs applied to both good-(Jansen et al.,
2008; Mersereau et al., 2008; Staessen et al., 2008; Meyer et al.,
2009) and poor-prognosis patients (Staessen et al., 2004; Stevens
et al., 2004; Debrock et al., 2007; Mastenbroek et al., 2007; Hardar-
son et al., 2008; Schoolcraft et al., 2009). These studies have all shown
that PGS using cleavage-stage biopsy and FISH does not improve the
live birth rate compared with a control group, and some of these
studies have shown harm or had to be terminated prematurely. The
American Society of Reproductive Medicine, the British Fertility
Society and the European Society of Human Reproduction and Embry-
ology (ESHRE) have all concluded that PGS, as it is currently practiced,
does not improve the live birth rates in patients with an advanced
maternal age, recurrent implantation failure or recurrent pregnancy
loss (Anderson, 2008; ASRM, 2008; Harper et al., 2011).
Many groups are investigating means to improve PGS, using
advanced testing methods or testing at different stages of embryo
development. The ESHRE PGS Task Force has chosen to evaluate
array technology at the polar body (PB) stage for evaluation. In
2008, the ESHRE PGS Task Force sought proposals for a molecular
test which had to be applicable on the ﬁrst and second PB (PB1and
PB2) (and zygotes for conﬁrmation) and able to identify whole
chromosome aneuploidy reliably within 12 h.
Only one prototype bacterial artiﬁcial chromosome (BAC) array
technology was put forward. However, it had not been clinically vali-
dated. The ESHRE PGS Task Force therefore undertook a
proof-of-principle study to investigate the feasibility and reliability of
this methodology. The speciﬁc objectives of this study were to
show that the analysis of both PBs could be completed within 12 h
and to ensure the reliable identiﬁcation of the chromosomal status
of a zygote in at least 90% of PB biopsy attempts. The latter objective
was evaluated by comparing the results obtained from the screened
PBs with those from the zygote.
Materials and Methods
Selection of experimental method
All relevant vendors at the annual meetings of the ESHRE and the Euro-
pean Society of Human Genetics in 2008 were invited to offer a molecular
test with the following requirements:
(1) It must be applicable at the single cell level for analysis of the PB1and
PB2, and zygotes (for conﬁrmation).
(2) It should reliably identify whole chromosome aneuploidy within 12 h
after receiving the sample.
(3) It must deliver an accurate reportable result in at least 90% of biopsy
attempts.
On 1 December 2008, a Task Force meeting was held in Geneva. At that
time, BlueGnome was the only applicant with an offer meeting these
speciﬁc requirements. It consisted of a BAC microarray-based 24 chromo-
some aneuploidy screening technology, originally developed for prenatal
diagnosis. After its presentation, it was decided to apply BlueGnome’s
technology in this proof-of-principle study.
Selection of study centres
On the basis of their experience with PB biopsy, two study centres were
selected: SISMER Bologna, Italy and the Department of Gynecological
Endocrinology & Reproductive Medicine at the University of Bonn,
Germany. Both participating centres had a documented record of
success with the clinical application of PB biopsy (Magli et al., 2004,
2011; Landwehr et al., 2008; Montag et al., 2009). Only experienced
and trained personnel were involved in performing the biopsies.
All data (patient and cycle data as well as array data) from both study
sites (PBs and oocytes) were evaluated by an independent data analysis
team at the University of Amsterdam.
Ethical approval
All patient materials were obtained and evaluated with informed patient
consent and under approval from the Ethics Committees from both
centres. The approval was given in Bologna by the Ethics Committee of
the SISMER center and in Bonn by the Local Ethics Committee
implemented for all medical research topics by the Medical Faculty at
the University of Bonn. Patients had to sign an informed consent prior
to entering the study
Patient inclusion
There were no restrictions with respect to the maternal age of the
patients. Only ICSI cycles were included. Micro-epididymal sperm aspira-
tion and testicular sperm extraction cycles were excluded, since they may
be associated with a higher incidence of male gonosomal aberrations and
thus could impact the concordance in zygote analysis.
Every treatment cycle included in the study was given a unique code.
This code consisted of a centre code (BLQ for Bologna and BON for
Bonn) together with a three digit number (001, 002, etc.). Patients were
numbered according to their date of inclusion.
Biopsy
Biopsy of the PB1and PB2 was performed between 6 and 9 h after inse-
mination by ICSI. Before the zygotes were biopsied, all adhering
cumulus cells were removed. PB1and PB2 were simultaneously removed
and separately processed for chromosomal analysis. In Bologna, mechan-
ical opening of the zona pellucida was performed. In Bonn, PB biopsy was
performed after laser-assisted opening of the zona pellucida. All manipula-
tions of PBs and zygotes were performed in a safety cabinet. All ampliﬁca-
tions were carried out in a class II Laminar ﬂow cabinet.
Workﬂow





(5) scanning and data analysis.
A clinical quality BAC microarray for the comparative hybridization of
ampliﬁed sample DNA against an ampliﬁed commercial control was
applied. Replication strategies and controls were used to deliver objective
and unambiguous estimation of aneuploidy at the whole chromosome
level.
For ampliﬁcation, the SurePlexTM kit was used to generate microgram
levels of DNA template from PBs and zygotes. Speciﬁc quality control
(QC) criteria for sample quality (size) and quantity (nanodrop) were
used to ensure that only speciﬁc ampliﬁcations were labelled, using a
quality-controlled labelling system (random primer, Cy dye).
PB samples were hybridized against male control DNA and the resulting
chromosome Y proﬁles were used as a QC check to determine the
3174 Geraedts et al.speciﬁcity ampliﬁcation/labelling by estimating how close proﬁles are to
the expected chromosome Y nullisomy.
The microarrays were scanned by making use of an Innopsys 710A
microarray scanner. This is an autofocus 3–40 mm resolution scanner,
which can produce data of high quality (www.innopsys.com). The Blue-
Fuse Multi-software ‘one button-’automated image analysis was used to
estimate copy number on the basis of multiple independent measurements
on each chromosome. Visualization and reporting of aneuploidy was on a
per chromosome basis. Only whole chromosome aneuploidies (gains and
losses) were scored. The PBs with ampliﬁcation but no diagnosis were
determined inconclusive. Structural chromosome defects have been
ignored for this analysis except for patients with a known maternal trans-
location (n ¼ 3).
Before starting the study, the laboratory personnel at both biopsy
centres were trained by BlueGnome to perform the microarray procedure
and analysis. This training included all stages of the 24sure protocol,
interpretation of QC data, software data analysis and reporting. Upon
completion of training BlueGnome independently validated each labora-
tory. A series of 25 ampliﬁcations were completed in Cambridge, UK
and distributed blindly to the study centres. Thereafter, a series of ﬁve
ampliﬁcations followed by another set of ampliﬁcations and labellings
were processed in the study centres and sent blinded to BlueGnome
for processing and evaluation.
One technician was able to process the samples alone, but for the diag-
nosis the calling from two independent technicians was requested.
Chromosomal analysis of zygotes
To estimate the concordance of the data from the PBs and the corre-
sponding zygotes, a blind analysis was carried out for those zygotes that
were presumably aneuploid based on the result of the chromosomal
analysis of their PBs.
Zygotes were also available for concordance testing under the following
circumstances:
† If one of the two PBs failed to amplify and the zygotes were not trans-
ferred, we deﬁned as abnormal a zygote with an aneuploid PB irrespec-
tive of not having a result from the other PB. Conversely, a zygote with
a normal PB and no result in the other was deﬁned as unknown;
† If an error occurred during meiosis I which was corrected in meiosis II
(so-called balanced euploid or aneuploid oocytes) and if these zygotes
were not transferred or frozen;
† If the results from the 24sure analysis were unclear and the zygotes
were not transferred.
From all these zygotes, the genetic material was ampliﬁed and half of the
ampliﬁed material (DNA) was sent to the other pilot study site for further
processing (labelling and hybridization) and blind evaluation of its aneu-
ploidy status under the code generated by the centre. The data obtained
from such zygotes were sent to Amsterdam where the data of the zygote
were matched with the data previously obtained from the corresponding
PBs.
The concordance analysis
All data (patient and cycle data as well as array data) from both study sites
(PBs and zygotes) were sent to Amsterdam for evaluation and data analy-
sis. The concordance analysis was made on the basis of three ploidy cat-
egories euploid/aneuploid/unknown. In the three cycles with patients that
had translocations, the concordance analysis was limited to the chromo-
somes not involved in the translocation. Discordant cases were reviewed
to determine which were truly discordant and which were the result of
technical artefacts.
Results
In the two study centres, a total of 41 patients undergoing ICSI treat-
ment were included (Table I). They underwent 42 cycles. An average
maternal age was 40.0+2.9 years. The mean number of mature
metaphase II oocytes obtained after ovarian hyperstimulation was 9.5.
On average 5.5 of these reached the 2 pronuclei (2PN) stage (range
1–15). Biopsy of both PBs was successful in 225 out of 226 zygotes.
The workﬂow was ﬁnished in 12 h in 33/42 (79%) cycles, while for
the remaining an extra hour was needed due to the higher number of
cells to be analysed. Whole genome ampliﬁcation (WGA) was
achieved in 214/226 (95%) of PB1 and array comparative genomic
hybridization (CGH) provided a result in 212: 90 (42%) were
euploid and 122 (58%) were aneuploid (Table II). WGA was also
achieved in 214/226 (95%) of PB2 and array CGH provided a result
in 207 (92%): 65 (31%) were euploid and 142 (69%) were aneuploid.
Some examples are given in Figs 1 and 2.
In 195 cases results from both PBs were obtained. These results
revealed that the chromosomal status of the zygote (i.e. the chromo-
somal status of the oocyte) was euploid in 55 (28%) cases and aneu-
ploid in 140 (72%) cases. In 41 out of 42 cycles, at least one zygote
was predicted to be aneuploid, whereas in 19 out of 42 (45%)
cycles all zygotes were predicted to be aneuploid. Thus, in 23 out
of 42 cycles a fresh transfer was possible (total number of embryos
transferred 37, average 1.6 per transfer). These transfers lead to
seven clinical pregnancies of which six evolutive (three twin pregnan-
cies and three singleton pregnancies). In addition, one frozen-thaw
cycle was performed on two euploid oocytes, which were frozen at
the 2PN stage. This cycle resulted in an ongoing singleton pregnancy.
In total, this results in a clinical pregnancy rate of 19% (8/42) per cycle
and 33% (8/24) per transfer and an ongoing pregnancy rate of 17%
(7/42) per cycle and (7/24) 29% per transfer. The implantation rate
was 26% per embryo transferred (10/39).
........................................................................................





Average age female 40.0




Average number of MFII 7.5
Average number of 2PN 5.5 Including
cryocycles









Pregnancy (+hCG) 7 17% 30% 8 33%
Clinical pregnancy 7 17% 30% 8 33%
Ongoing pregnancy 6 14% 26% 7 29%
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gletons) and all are apparently healthy. Two of the ﬁve singleton births
resulted from pregnancies in which two embryos implanted. In the ﬁrst
pregnancy one baby was born, while one fetus died at Week 26; the
chromosomal analysis revealed a normal karyotype. In the other preg-
nancy one sac vanished.
A total of 177 untransferred zygotes were available for concordance
analysis. A result was obtained in 156, of which 38 (24%) were euploid
and 118 (76%) were aneuploid. Of these 156 zygotes, 18 could not be
included in the concordance analysis because the diagnosis of the PB
was unknown (n ¼ 5), the ploidy of the oocyte could not be predicted
because of compensated aneuploidy in PB1 and PB2 (n ¼ 7), or the
result of the zygote was obscured by cumulus cell contamination
(n ¼ 6). The presence of cumulus cells in the zona pellucida could
affect the quality of results considerably. This was especially evident
in the analysis of the latter six oocytes in which the low standard devi-
ation of the clones along the mean line was indicative of possible
external DNA contamination (Fig. 3). The presence of this contami-
nating normal DNA makes the speciﬁc gain and losses very subtle.
Further evidence of possible maternal contamination is that the scan
images of the six oocytes in which cumulus cell contamination was sus-
pected were all apparently female. All of these oocytes had been pre-
pared by Pronase treatment.
Of the remaining 138 oocyte/PB pairs, 130 (94%) were concordant
and 8 were discordant. Table III shows the eight discordant cases; in
seven cases where the PBs indicated aneuploidy and the zygote was
euploid, and in one case where the PBs indicated euploidy and the
zygote was aneuploid. In the latter case, the zygote was not trans-
ferred because it contained an unbalanced translocation. There was
not a signiﬁcant difference in the concordance rate between the
two centres.
Discussion
This study was undertaken to determine whether biopsy of the PB1
and PB2 followed by a subsequent analysis of the complete chromo-
some complement of these PBs using array-based CGH enables a
reliable, timely and accurate identiﬁcation of the maternal contribution
to the chromosomal status of the corresponding zygote.
Our ﬁrst aim was to demonstrate that microarray analysis of both
PBs could be completed within 12 h. We chose this time period as
this would allow for fresh transfer in all countries around the globe,
........................................................................................
Table II Ploidy status of PBs and oocytes.
(%)
PB1
Total number biopsied 226
Total number ampliﬁed 214 95
Euploid 90 40 42% of 212 diagnosed
Aneuploid 122 54 58% of 212 diagnosed
Unknown 14 6
PB2
Total number biopsied 226
Total number ampliﬁed 214 95
Euploid 65 29 31% of 207 diagnosed
Aneuploid 142 63 69% of 207 diagnosed
Unknown 19 8
All PBs
Total number biopsied 452
Total number ampliﬁed 428 95
Euploid 155 34 37% of 419 diagnosed
Aneuploid 264 58 63% of 419 diagnosed
Unknown 33 8
Predicted oocytes
Total number biopsied 226




Total number analyzsed 177
Total number result 156 88
Euploid 38 24
Aneuploid 118 76
Figure 1 Results from a PB I carrying a loss of chromosome 14. All other non-sex chromosomes are within the bounds of normality.
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such as Germany and Switzerland.
The workﬂow took .12 h when there were more than six
embryos. The speed of the workﬂow can be further increased by
automation of labelling, hybridization and scanning, which will allow
for the analysis of all embryos within a 12-h time frame. In countries
where there are no restrictive laws in terms of timing of embryo selec-
tion, some steps in the workﬂow can be extended to an overnight
procedure so that all of the steps of the workﬂow for which the pres-
ence of skilled personnel is necessary can be accommodated during
normal working hours. Thus, the results for all embryos should be
available on Day 2 of preimplantation development.
The second aim of our study was the reliable and accurate identiﬁ-
cation of the maternal contribution to the chromosomal status of the
zygote in 90% or more of cases. Reasons for diagnostic problems were
mainly failed ampliﬁcation or hybridization, or inconclusive results
because of high noise of the signals. Regarding the failed ampliﬁcation,
it was clear that special attention has to be paid to the transfer of the
PB to the corresponding PCR tube, whereas for the following steps, a
critical point is represented by the desiccation and resuspension of the
pellets after labelling.
In this study, the rate of concordance between PBs and zygotes has
been studied for all chromosomes. This was considered to be a key
point for the evaluation of the procedure.
During the past 10–15 years, PGS has been extensively applied,
mainly by FISH on blastomeres biopsied from cleavage-stage
embryos. The reported data show that, depending on the method
used, the error rate can vary between 2 and 50% (Munne et al.,
2002; Baart et al., 2004; Li et al., 2005; Colls et al., 2007; Magli
et al., 2007; Gutierrez-Mateo et al., 2011).
The concordance rate between the array CGH results for both PBs
and that for the corresponding zygote was 94% (130/138). In seven of
the eight discordant cases, one or both PBs were aneuploid and the
zygote was euploid. The discordant cases might have originated
from the compensation of aneuploidy by the sperm or from anaphase
lagging, especially at meiosis II, leaving behind some chromosomes in
the oocyte which would then be degraded to make the resulting
zygote euploid. Spurious results might also be caused by fragmentation
Figure 2 Polar body II with losses of chromosomes 6, 14, 16, 19 and gain of chromosome 20.
Figure 3 Possible contamination by cumulus cells in an oocyte that was predicted to be aneuploid, for chromosomes 12, 18 and 19. The contami-
nation by foreign DNA is suspected due to the low, standard deviation of all clones and the faint shifts for the predicted aneuploid chromosomes 12
(gain), 18 (loss) and 19 (loss).
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fragmentation was very infrequent. In most cases, it was actually poss-
ible to distinguish the PB2 from the PB1, due in part to the experience
gained in biopsying oocytes and to the now-prevalent careful scoring
of the PB1 morphology when doing ICSI. Therefore, relevant notes
were taken in the working sheets and in cases of fragmented PB1,
special care was taken to remove and transfer all fragments in the cor-
responding reaction tube. Comprehensive methodological aspects and
detailed analysis of the results at the level of individual chromosome
and chromatid abnormalities are published separately (Magli et al.,
2011).
The proportion of aneuploid zygotes in these patients was very
high. The analysis of the data from the oocytes that were diagnosed
as aneuploid by array CGH showed that 76.3% of the corresponding
aneuploidies would have been detected using a conventional ﬁve-
colour FISH probe set for chromosomes 13, 16, 18, 21 and 22. As
a result 38 embryos classiﬁed as abnormal using array CGH would
have been classiﬁed as normal using ﬁve-colour FISH as they involved
aneuploidies not included in the usual FISH panel.
Furthermore, a very high incidence of multiple aneusomies was
observed, although a relatively small number of aneusomies were
potentially viable. The reasons for these might be truly biological
[for example as a result of advanced maternal age or related to
assisted reproduction technology (ART)] or technical
(array-CGH-related). The analysis of PB2 adds signiﬁcantly to
achieve prediction of the oocyte ploidy. PB1 analysis alone only
detects 70% of aneuploid oocytes and only half of the viable aneuso-
mies. These results are in contrast to the data published by Sher et al.
where the analysis of PB2 did not result in a gain in information follow-
ing CGH (Sher et al., 2007).
The BAC microarrays that have been used in this study are based
on a form of CGH that was originally developed to analyse aneuploidy
in cancer (Kallioniemi et al., 1992). At that time both the test DNA
and the reference DNA were labelled with two different ﬂuoro-
chromes and hybridized simultaneously onto normal male metaphase
chromosomes. This method was ﬁrst used on preimplantation
embryos by Voullaire et al. (2000) and Wells and Delhanty (2000 ).
In 2001, the ﬁrst successful clinical application for aneuploidy detection
after IVF was reported by Wilton et al. (2001). The application of this
nowadays so-called ‘classical’ CGH is hampered by the amount of
DNA and the time required for the analysis. The ﬁrst clinical appli-
cation of metaphase CGH on PBs was already reported in 2002
(Wells et al., 2002). However, this method has never been used on
a large-scale since then because it requires experience and is labour
intensive. Therefore, the development of a simpler and more rapid
CGH methodology was needed. The ﬁrst clinical application of the
combination of WGA of PB1 and BAC microarray analysis has recently
been achieved by Fishel et al. who reported the birth of a normal
healthy baby (Fishel et al., 2010).
In conclusion, our study clearly demonstrates that chromosome
aneuploidy of the oocyte can reliably and timely be predicted by
array CGH analysis of both PBs. Aneuploidy appears the predominant
cause of non-viability at least in this group of patients. Further pro-
gress, in the course of this project, will move the technique from
the pilot phase to a clinical validation phase. The aim of this progress
is not only to demonstrate that it is possible to have a reliable and
accurate diagnosis on PBs but also that this approach is effective in
improving ART results. The next question that needs to be answered
is ‘Does this method decrease the time to pregnancy by allowing the
early transfer of euploid embryos and by avoiding the transfer of aneu-
ploid embryos?’ Given the large proportion of women having no
euploid oocytes, a second question might be addressed: ‘Can this
method reliably predict which group of patients has a very low
chance of pregnancy?’ Only by testing these questions in a randomized
clinical trial can the applicability and value of this approach be proved.
The ESHRE PGS Task Force hopes to be able to address these impor-
tant questions in a multicentre randomized trial to be started in 2011
based on the technology used in the pilot study.
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Table III Analysis of eight discordant cases.
Case Result from PB1 analysis Result from PB2 analysis Predicted oocyte ploidy Evaluation of oocytes
1 Gain 17,20,21; Loss 13,22 Gain 13,22; Loss 17,20,21; partial 9
a Gain partial 9; Loss- Euploid
d
2 Gain 2,20; partial 15; Loss - Gain -; Loss 15 Gain -; Loss 2,20; partial 15 Euploid
d
3 Gain 21,X; Loss 15 Gain 15; Loss - Gain -; Loss 21,X Euploid
d
4 Gain -; Loss- Gain -; Loss 21,22 Gain 21,22; Loss - Euploid
5 Gain -; Loss partial 1p, partial 9
b Gain -; Loss - Gain partial 1p, partial 9; Loss - Euploid
c
6 Gain 11p; Loss 9,19p Gain -; Loss 11p Gain 9,19p; Loss - Euploid for chr. 9
c
7 Gain -; Loss 11q Gain 11q; Loss 19q Gain 19q; Loss - Gain 19q; Loss 2,3,17,20,11p
8 Gain 13,14; Loss - Gain -; Loss 14 Gain -; Loss 13 Euploid
d
aThe partial loss involved seven BAC clones and was therefore considered a relevant aneuploidy.
bThe partial loss involved ﬁve BAC clones for chromosomes 1 and 7 for chromosome 9 and was therefore considered a relevant aneuploidy.
cCases 5 and 6 were from a patient with a balanced translocation and the chromosomes involved in the translocation (46,XX,t(11;19);(11q.10;19p.10) were excluded from the
concordance analysis for aneuploidy.
dIn cases where for one or more chromosomes losses were observed in one PB and gains in another, the deviation of the losses/gains from the euploidy base line were evaluated. For
the cases 1, 2, 3 and 8, the oocytes were predicted to be compensated euploid for the indicated chromosomes.
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